Massachusetts H4339 mandates coverage for biomarker testing for insured individuals.

Massachusetts H4339 requires health insurers and managed care organizations to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases. Biomarker testing includes analysis of tissue, blood, or other biospecimens for biomarkers such as gene mutations or protein expression. Coverage must be provided when supported by medical and scientific evidence, including FDA-approved tests or drugs, and clinical guidelines. Insurers must respond to prior authorization requests within 72 hours, or 24 hours if delay risks the patient's health.

Massachusetts H4339 mandates coverage for biomarker testing for insured individuals.

Massachusetts H4339 requires health insurers and managed care organizations to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases. Biomarker testing includes analysis of tissue, blood, or other biospecimens for biomarkers such as gene mutations or protein expression. Coverage must be provided when supported by medical and scientific evidence, including FDA-approved tests or drugs, and clinical guidelines. Insurers must respond to prior authorization requests within 72 hours, or 24 hours if delay risks the patient's health.